Effect of Carbogen to Chemoradiation in Volume of Rectal Cancer
-
Christina Hari Nawangsih
,
Soehartati Gondowihardjo
,
Sofia Mubarika Haryana
,
Soeharyo Hadisaputro
,
Catharina Suharti
,
Edi Dharmana
,
Hermina Sukmaningtyas
,
Fifin Luthfia Rahmi
,
Ignatius Riwanto
Abstract
The outcome of inoperable rectal cancer treatment by chemotherapy, radiotherapy, and targeted therapy are still unfavorable. Carbogen is a combination of 98% oxygen and 2% carbon dioxide proven effective as chemoradiosensitizer. The aim of this study is to know the effect of concurrent carbogen and chemoradiotherapy in locally advanced rectal cancer by measuring the shrinkage of the tumor volume. The design of this study was randomized true experimental 2 groups pre and post-test-controlled design. Samples were patients with locally advanced rectal cancer. MRI of the pelvis before and 4-8 weeks after the chemoradiation were examined. A total of 28 subjects were randomized to 14 patients who received concurrent chemoradiation with carbogen (treatment group) and 14 patients chemoradiation (control) The tumor shrinkage in the treatment group (13.08 to 6.08 cm3) was significantly higher compared to the control group (18.00 to 12.83 cm3). Supplementation of carbogen to standard treatment chemoradiation for locally advanced rectal cancer significantly shrinkage the tumor volume.
1. World Health Organization. Country-specific, Incidence Method, National Country-specific, Mortality. World Heal Organ. 2018;
2. Yin D, Morris CR, Bates JH, German RR. Effect of Misclassified Underlying Cause of Death on Survival Estimates of Colon and Rectal Cancer. J Natl Cancer Ist. 2011;103(14):1–4.
3. Society AC. Colorectal Cancer Facts & Figures 2017 - 2019. Atlanta; 2017.
4. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.
5. Willett CG, Czito BG. Neoadjuvant Chemoradiation for Rectal Cancer. Seminars in Colon and Rectal Surgery. Elsevier Inc.; 2008. p. 197–202.
6. Wang SJ, Fuller CD, Emery R, Thomas CR. Conditional Survival in Rectal Cancer : A SEER Database Analysis. Gastrointest Cancer Res. 2007;1(3):84–9.
7. National Commitee for Cancer Care. National Guidelines for Colorectal Cancer Health Care. National Guidelines for Cancer Care. 1st ed. Jakarta: Ministry of Health of the Republic of Indonesia; 2017.
8. National Comprehensip Cancer Network.org. Rectal Cancer. 2018.
9. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994/09/10. 1994;344(8924):707–11.
10. Ais Conde G, Fadrique Fernández B, Vázquez Santos P, López Pérez J, Picatoste Merino M, Manzanares Sacristán J. Rectal cancer: Which patients benefit from radiotherapy. Cirugía Española (English Ed. Elsevier; 2010;87(6):350–5.
11. Bedi M, Das P, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, et al. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res. 2007 Mar;1(2):44–8.
12. Gérard J-P, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P, et al. Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer : Results of the Phase III Trial ACCORD 12 / 0405-Prodige 2. J Clin Oncol. 2010 Apr;28(10):1638–44.
13. Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, et al. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012 Mar;82(4):1367–75.
14. Gunderson LL tapper EJ, editor. Clinical Radiation Oncology. 3rd ed. Philadelphia: Saunders, am imprint of Elsevier Inc; 2012. 23–28 p.
15. William C Dewey JSB. radiobiologic principles. In: Phillips L, editor. Textbook of Radiation Oncology. 2nd ed. Philadelphia: Saunders Elseveir Inc; 2004. p. 3–76.
16. Edward C. Halperin, Luther W. Brady, Carlos A. Perez DEW. Perez & Brady’s Principles and Practice of Radiation Oncology. 6th ed. Wolter Kluwer Lippincott Williams& Wilkins; 2013. p. 350–3.
17. G. Gordon Steel. Clonogenic Cells and the concept of cell survival. In: Steel GG, editor. Basic Clinical Radiobiology. 2 nd ed. New York: Oxford University Press Inc.; 1997. p. 40–51.
18. Moen I, Stuhr LEB. Hyperbaric oxygen therapy and cancer—a review. Target Oncol. 2012;233–42.
19. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010;28(33):4912–8.
20. van Weelden WJ, Sekarutami SM, Bekkers RLM, Kaanders JH, Bussink J, Gondhowiardjo S, et al. The effect of carbogen breathing and nicotinamide added to standard (chemo)radiation treatment of advanced cervical cancer in Indonesia. Int J Gynecol Cancer. 2014;24(9):1628–35.
21. Zhan HW, Liu HB, Bao CK, Ye XJ, Zhang H, He GQ. Effect of carbogen on tumour oxygenation and 32P-colloid intersitial irradiation response. Med Sci Monit. 2010;16(1):BR11–6.
22. Ramaiya NH, Ad A. Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. AJR. 2010;195(August 2010):281–9.
23. Zackrisson B, Franzén L, Henriksson R, Littbrand B, Dennis M, Rojas AM, et al. Acute Effects of Accelerated Radiotherapy in Combination with Carbogen Breathing and Nicotinamide ( Arcon ) With Carbogen Breathing And Nicotinamide ( ARCON ). Acta Oncol. 2009;33(4):377–81.
24. Alonzi R, Padhani AR, Maxwell RJ, Taylor NJ, Stirling JJ, Wilson JI, et al. Carbogen breathing increases prostate cancer oxygenation : a translational MRI study in murine xenografts and humans. Br J Cancer. 2009;100:644–8.
25. Resch G, Vries A De, Öfner D, Eisterer W, Rabl H. Preoperative treatment with capecitabine , bevacizumab and radiotherapy for primary locally advanced rectal cancer – A two stage phase II clinical trial q. Radiother Oncol. Elsevier Ireland Ltd; 2012;102(1):10–3.
26. Louis B. Harrison, Manjeet Chadha, Richard J. Hill, Hu, Kenneth, Daniel S. Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes. Oncologist. 2002;7:492–508.
27. Schuuring J, Bussink J, Bernsen HJJA, Peeters W, Van Der Kogel AJ. Effect of carbogen breathing on the radiation response of a human glioblastoma xenograft: Analysis of hypoxia and vascular parameters of regrowing tumors. Strahlentherapie und Onkol. 2006;182(7):408–14.
28. Wang L, Gao S, Jiang W, Luo C, Xu M, Bohlin L, et al. Antioxidative dietary compounds modulate gene expression associated with apoptosis, DNA repair, inhibition of cell proliferation and migration. Int J Mol Sci. 2014;15(9):16226–45.
29. Tian H, Gao Z, Li HZ, Zhang BF, Wang G, Zhang Q, et al. DNA damage response - A double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2015;358(1):8–16.
30. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer. 2002;38(2):223–30.
31. Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, et al. 5-FU metabolism in cancer and orally-administrable 5-FU drugs. Cancers (Basel). 2010;2(3):1717–30.
32. Zoroquiain P, Nayman T, Fernandes B, Burnier MN. Conjunctival melanoma with morphologic diversity and orbital invasion. Am J Dermatopathol. 2016;38(5):e52–6.
2. Yin D, Morris CR, Bates JH, German RR. Effect of Misclassified Underlying Cause of Death on Survival Estimates of Colon and Rectal Cancer. J Natl Cancer Ist. 2011;103(14):1–4.
3. Society AC. Colorectal Cancer Facts & Figures 2017 - 2019. Atlanta; 2017.
4. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.
5. Willett CG, Czito BG. Neoadjuvant Chemoradiation for Rectal Cancer. Seminars in Colon and Rectal Surgery. Elsevier Inc.; 2008. p. 197–202.
6. Wang SJ, Fuller CD, Emery R, Thomas CR. Conditional Survival in Rectal Cancer : A SEER Database Analysis. Gastrointest Cancer Res. 2007;1(3):84–9.
7. National Commitee for Cancer Care. National Guidelines for Colorectal Cancer Health Care. National Guidelines for Cancer Care. 1st ed. Jakarta: Ministry of Health of the Republic of Indonesia; 2017.
8. National Comprehensip Cancer Network.org. Rectal Cancer. 2018.
9. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994/09/10. 1994;344(8924):707–11.
10. Ais Conde G, Fadrique Fernández B, Vázquez Santos P, López Pérez J, Picatoste Merino M, Manzanares Sacristán J. Rectal cancer: Which patients benefit from radiotherapy. Cirugía Española (English Ed. Elsevier; 2010;87(6):350–5.
11. Bedi M, Das P, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, et al. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res. 2007 Mar;1(2):44–8.
12. Gérard J-P, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P, et al. Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer : Results of the Phase III Trial ACCORD 12 / 0405-Prodige 2. J Clin Oncol. 2010 Apr;28(10):1638–44.
13. Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, et al. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012 Mar;82(4):1367–75.
14. Gunderson LL tapper EJ, editor. Clinical Radiation Oncology. 3rd ed. Philadelphia: Saunders, am imprint of Elsevier Inc; 2012. 23–28 p.
15. William C Dewey JSB. radiobiologic principles. In: Phillips L, editor. Textbook of Radiation Oncology. 2nd ed. Philadelphia: Saunders Elseveir Inc; 2004. p. 3–76.
16. Edward C. Halperin, Luther W. Brady, Carlos A. Perez DEW. Perez & Brady’s Principles and Practice of Radiation Oncology. 6th ed. Wolter Kluwer Lippincott Williams& Wilkins; 2013. p. 350–3.
17. G. Gordon Steel. Clonogenic Cells and the concept of cell survival. In: Steel GG, editor. Basic Clinical Radiobiology. 2 nd ed. New York: Oxford University Press Inc.; 1997. p. 40–51.
18. Moen I, Stuhr LEB. Hyperbaric oxygen therapy and cancer—a review. Target Oncol. 2012;233–42.
19. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010;28(33):4912–8.
20. van Weelden WJ, Sekarutami SM, Bekkers RLM, Kaanders JH, Bussink J, Gondhowiardjo S, et al. The effect of carbogen breathing and nicotinamide added to standard (chemo)radiation treatment of advanced cervical cancer in Indonesia. Int J Gynecol Cancer. 2014;24(9):1628–35.
21. Zhan HW, Liu HB, Bao CK, Ye XJ, Zhang H, He GQ. Effect of carbogen on tumour oxygenation and 32P-colloid intersitial irradiation response. Med Sci Monit. 2010;16(1):BR11–6.
22. Ramaiya NH, Ad A. Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. AJR. 2010;195(August 2010):281–9.
23. Zackrisson B, Franzén L, Henriksson R, Littbrand B, Dennis M, Rojas AM, et al. Acute Effects of Accelerated Radiotherapy in Combination with Carbogen Breathing and Nicotinamide ( Arcon ) With Carbogen Breathing And Nicotinamide ( ARCON ). Acta Oncol. 2009;33(4):377–81.
24. Alonzi R, Padhani AR, Maxwell RJ, Taylor NJ, Stirling JJ, Wilson JI, et al. Carbogen breathing increases prostate cancer oxygenation : a translational MRI study in murine xenografts and humans. Br J Cancer. 2009;100:644–8.
25. Resch G, Vries A De, Öfner D, Eisterer W, Rabl H. Preoperative treatment with capecitabine , bevacizumab and radiotherapy for primary locally advanced rectal cancer – A two stage phase II clinical trial q. Radiother Oncol. Elsevier Ireland Ltd; 2012;102(1):10–3.
26. Louis B. Harrison, Manjeet Chadha, Richard J. Hill, Hu, Kenneth, Daniel S. Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes. Oncologist. 2002;7:492–508.
27. Schuuring J, Bussink J, Bernsen HJJA, Peeters W, Van Der Kogel AJ. Effect of carbogen breathing on the radiation response of a human glioblastoma xenograft: Analysis of hypoxia and vascular parameters of regrowing tumors. Strahlentherapie und Onkol. 2006;182(7):408–14.
28. Wang L, Gao S, Jiang W, Luo C, Xu M, Bohlin L, et al. Antioxidative dietary compounds modulate gene expression associated with apoptosis, DNA repair, inhibition of cell proliferation and migration. Int J Mol Sci. 2014;15(9):16226–45.
29. Tian H, Gao Z, Li HZ, Zhang BF, Wang G, Zhang Q, et al. DNA damage response - A double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2015;358(1):8–16.
30. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer. 2002;38(2):223–30.
31. Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, et al. 5-FU metabolism in cancer and orally-administrable 5-FU drugs. Cancers (Basel). 2010;2(3):1717–30.
32. Zoroquiain P, Nayman T, Fernandes B, Burnier MN. Conjunctival melanoma with morphologic diversity and orbital invasion. Am J Dermatopathol. 2016;38(5):e52–6.
| Files | ||
| Issue | Vol 58, No 1 (2020) | |
| Section | Articles | |
| DOI | https://doi.org/10.18502/acta.v58i1.3702 | |
| Keywords | ||
| Rectal cancer Carbogen Chemoradiation Volume | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Nawangsih C, Gondowihardjo S, Haryana S, Hadisaputro S, Suharti C, Dharmana E, Sukmaningtyas H, Rahmi F, Riwanto I. Effect of Carbogen to Chemoradiation in Volume of Rectal Cancer. Acta Med Iran. 2020;58(1):15-20.
